{"entity":{"id":"rebecca-dent","kind":"person","name":"Rebecca Dent","aka":[],"tldr":"Breast medical oncologist and Deputy CEO for clinical operations at the National Cancer Centre Singapore, an international leader in triple-negative breast cancer trials.","summary":"Rebecca Dent is Deputy Chief Executive Officer for clinical operations at the National Cancer Centre Singapore and a senior consultant in medical oncology. Her research focuses on triple-negative and early breast cancer, and she has been a lead investigator on international phase 3 trials of immunotherapy and targeted agents in breast cancer. She chairs and contributes to international breast cancer guideline and consensus groups.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.nccs.com.sg/about-nccs/leadership.html"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dent+R%5BAuthor%5D+breast"}],"tags":["leadership","clinician-scientist","breast cancer"],"related":[],"cancers":["tnbc","breast-hr-positive","breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["nccs"],"pathways":[],"terms":[],"trials":["keynote-522","impassion130","tropion-breast02"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["breast-cancer-research-and-treatment"],"dependsOn":[],"notes":[],"role":"Deputy Chief Executive Officer (Clinical)","institutionId":"nccs","specialisms":["Breast cancer","Triple-negative breast cancer","Clinical trials"],"profiles":[{"label":"Institution profile","url":"https://www.nccs.com.sg/about-nccs/leadership.html"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dent+R%5BAuthor%5D+breast"}],"papers":[{"title":"Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer","journal":"Breast Cancer Research and Treatment","year":2021,"doi":"10.1007/s10549-021-06143-5"},{"title":"Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial","journal":"The Lancet Oncology","year":2021,"doi":"10.1016/s1470-2045(20)30754-3"},{"title":"Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","journal":"The Lancet Oncology","year":2017,"doi":"10.1016/s1470-2045(17)30450-3"}],"orcid":"0000-0001-6421-7602"},"route":"/people/rebecca-dent/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"institution":[{"id":"nccs","kind":"institution","name":"National Cancer Centre Singapore","route":"/institutions/nccs/"}],"trial":[{"id":"impassion130","kind":"trial","name":"IMpassion130","route":"/trials/impassion130/"},{"id":"keynote-522","kind":"trial","name":"KEYNOTE-522","route":"/trials/keynote-522/"},{"id":"tropion-breast02","kind":"trial","name":"TROPION-Breast02","route":"/trials/tropion-breast02/"}],"journal":[{"id":"breast-cancer-research-and-treatment","kind":"journal","name":"Breast cancer research and treatment","route":"/journals/breast-cancer-research-and-treatment/"}],"paper":[{"id":"paper-tropion-breast02-ann-oncol-2026","kind":"paper","name":"Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial","route":"/key-papers/paper-tropion-breast02-ann-oncol-2026/"},{"id":"paper-kim-lotus-ipatasertib-tnbc-lancet-oncol-2017","kind":"paper","name":"Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","route":"/key-papers/paper-kim-lotus-ipatasertib-tnbc-lancet-oncol-2017/"},{"id":"paper-dent-tnbc-clinical-features-recurrence-ccr-2007","kind":"paper","name":"Triple-negative breast cancer: clinical features and patterns of recurrence","route":"/key-papers/paper-dent-tnbc-clinical-features-recurrence-ccr-2007/"}],"roadmap":[{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/"}]}}